Daniel E Casey

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. doi request reprint Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia
    Daniel E Casey
    Oregon Health and Science University, Portland, OR 97239, USA
    Neuropsychopharmacology 34:1330-8. 2009
  2. doi request reprint Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study
    Daniel E Casey
    UHN 80 Department of Psychiatry, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    Psychopharmacology (Berl) 200:317-31. 2008
  3. ncbi request reprint Implications of the CATIE trial on treatment: extrapyramidal symptoms
    Daniel E Casey
    Department of Psychiatry, Oregon Health and Science University, Portland, OR 97239, USA
    CNS Spectr 11:25-31. 2006
  4. ncbi request reprint Metabolic issues and cardiovascular disease in patients with psychiatric disorders
    Daniel E Casey
    UHN 80 Department of Psychiatry, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97239, USA
    Am J Med 118:15S-22S. 2005
  5. ncbi request reprint Dyslipidemia and atypical antipsychotic drugs
    Daniel E Casey
    Department of Psychiatry, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    J Clin Psychiatry 65:27-35. 2004
  6. ncbi request reprint Pathophysiology of antipsychotic drug-induced movement disorders
    Daniel E Casey
    Department of Psychiatry and Neurology, Oregon Health and Sciences University, Portland, OR 97321, USA
    J Clin Psychiatry 65:25-8. 2004
  7. doi request reprint A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive
    Ira D Glick
    Department of Psychiatry, Schizophrenia Clinic, Stanford University School of Medicine, Stanford, CA, USA
    J Clin Psychopharmacol 29:267-71. 2009
  8. ncbi request reprint Metabolic effects of treatment with atypical antipsychotics
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY, USA
    J Clin Psychiatry 65:1447-55. 2004
  9. ncbi request reprint Atypical antipsychotics: enhancing healthy outcomes
    Daniel E Casey
    Mental Illness Research, Education and Clinical Center, MIRECC VISN 20, Portland VA Medical Center and the Department of Psychiatry, Oregon Health Sciences University, Portland, OR 97201, USA
    Arch Psychiatr Nurs 16:S12-9. 2002
  10. ncbi request reprint Long-term treatment goals: enhancing healthy outcomes
    Daniel E Casey
    Oregon Health and Science University, Portland, Oregon, USA
    CNS Spectr 8:26-8. 2003

Detail Information

Publications19

  1. doi request reprint Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia
    Daniel E Casey
    Oregon Health and Science University, Portland, OR 97239, USA
    Neuropsychopharmacology 34:1330-8. 2009
    ....
  2. doi request reprint Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study
    Daniel E Casey
    UHN 80 Department of Psychiatry, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    Psychopharmacology (Berl) 200:317-31. 2008
    ..Bifeprunox is a partial dopamine agonist with a unique receptor-binding profile and potential antipsychotic properties...
  3. ncbi request reprint Implications of the CATIE trial on treatment: extrapyramidal symptoms
    Daniel E Casey
    Department of Psychiatry, Oregon Health and Science University, Portland, OR 97239, USA
    CNS Spectr 11:25-31. 2006
    ..This article explores the reported results of the CATIE trial regarding EPS and emphasizes the differentiation of the atypicals from perphenazine on EPS and how these results should be incorporated into daily practice for the clinician...
  4. ncbi request reprint Metabolic issues and cardiovascular disease in patients with psychiatric disorders
    Daniel E Casey
    UHN 80 Department of Psychiatry, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97239, USA
    Am J Med 118:15S-22S. 2005
    ..The costs associated with the treatment of the metabolic syndrome, diabetes, and coronary heart disease in populations with schizophrenia are also described...
  5. ncbi request reprint Dyslipidemia and atypical antipsychotic drugs
    Daniel E Casey
    Department of Psychiatry, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    J Clin Psychiatry 65:27-35. 2004
    ....
  6. ncbi request reprint Pathophysiology of antipsychotic drug-induced movement disorders
    Daniel E Casey
    Department of Psychiatry and Neurology, Oregon Health and Sciences University, Portland, OR 97321, USA
    J Clin Psychiatry 65:25-8. 2004
    ..A number of factors contribute to the difficult task of gaining insight into the pathophysiologic processes of antipsychotic agents and why these agents may lead to drug-induced movement disorders...
  7. doi request reprint A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive
    Ira D Glick
    Department of Psychiatry, Schizophrenia Clinic, Stanford University School of Medicine, Stanford, CA, USA
    J Clin Psychopharmacol 29:267-71. 2009
    ..To compare the efficacy of mood stabilizer augmentation of an antipsychotic for patients with schizophrenia who are both stabilized and partially responsive...
  8. ncbi request reprint Metabolic effects of treatment with atypical antipsychotics
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY, USA
    J Clin Psychiatry 65:1447-55. 2004
  9. ncbi request reprint Atypical antipsychotics: enhancing healthy outcomes
    Daniel E Casey
    Mental Illness Research, Education and Clinical Center, MIRECC VISN 20, Portland VA Medical Center and the Department of Psychiatry, Oregon Health Sciences University, Portland, OR 97201, USA
    Arch Psychiatr Nurs 16:S12-9. 2002
  10. ncbi request reprint Long-term treatment goals: enhancing healthy outcomes
    Daniel E Casey
    Oregon Health and Science University, Portland, Oregon, USA
    CNS Spectr 8:26-8. 2003
    ..These drugs are likely to provide physicians with an increasingly viable option in the long-term treatment and rehabilitation of patients with schizophrenia...
  11. ncbi request reprint Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study
    Daniel E Casey
    Mental Health Division P3MIRECC, VA Medical Center, 3710 SW US Veterans Hospital Road, Portland, OR 97239, USA
    Psychopharmacology (Berl) 166:391-9. 2003
    ..It is important to compare switching strategies to determine which methods produce the best possible patient outcomes...
  12. ncbi request reprint Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia
    Daniel E Casey
    Mental Illness Research, Education, and Clinical Center, Portland VA Medical Center, OR 97201, USA
    Neuropsychopharmacology 28:182-92. 2003
    ..Further evaluation is warranted to confirm these findings...
  13. ncbi request reprint Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo
    Gilbert J L'italien
    Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492, USA
    J Clin Psychiatry 68:1510-6. 2007
    ....
  14. ncbi request reprint Physical health monitoring of patients with schizophrenia
    Stephen R Marder
    Department of Veterans Affairs Greater Los Angeles Healthcare System, CA, USA
    Am J Psychiatry 161:1334-49. 2004
    ..The authors discuss a consensus panel's recommendations for improving the physical health monitoring of patients with schizophrenia who are treated in outpatient settings...
  15. ncbi request reprint Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    Psychiatr Serv 55:290-4. 2004
    ....
  16. ncbi request reprint Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia
    Daniel E Casey
    J Clin Psychiatry 65:4-18; quiz 19-20. 2004
  17. ncbi request reprint Response to letter to the editor by Dr Mackin
    Charles H Hennekens
    Am Heart J 152:e59. 2006
  18. ncbi request reprint Schizophrenia and increased risks of cardiovascular disease
    Charles H Hennekens
    Department of Biomedical Science, Center of Excellence in Biomedical and Marine Biotechnology, Florida Atlantic University, FL, USA
    Am Heart J 150:1115-21. 2005
    ..The aim of the study is to review the absolute and relative impacts of the major causes for premature mortality among patients with schizophrenia...
  19. ncbi request reprint Effect of a novel potential atypical antipsychotic drug, Y-931, in producing dystonia in cebus monkeys
    Yasuyuki Shiigi
    Research Laboratory I CNS, Pharmaceuticals Research Unit, Research and Development Division, Mitsubishi Pharma Corporation, Iruma, Saitama, Japan
    J Pharmacol Sci 93:364-6. 2003
    ..5 mg/kg, i.m., the scores did not exceed 20, up to a dose of 1.0 mg/kg, i.m. and lacked a dose-response relationship. The present result suggests that Y-931 is predicted to have a low risk of extrapyramidal side effects...